FDA's Overhaul Of GMP Oversight Will Include Numerous Targeted Guidances
This article was originally published in The Pink Sheet Daily
Executive Summary
The initiative to develop risk-based oversight of drug manufacturing will enter a new, less frenetic phase at its two-year anniversary in August. The project is a carryover from Deputy Commissioner Crawford's first term as acting head of FDA.